All In Biotech

Drug Trial Radar · NCT07540832

A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC

An Open-Label Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced Hepatocellular Carcinoma as Second Line Therapy

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Sep 2028

Study completion Oct 2028

Sponsor

Sponsor type
Industry
First posted
Apr 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer.

Conditions

  • Advanced Hepatocellular Carcinoma (HCC)

Interventions

  • WGI-0301Drug

    WGI-0301 at Maximum Tolerated Dose (MTD)

  • WGI-0301Drug

    WGI-0301 at dose level below Maximum Tolerated Dose (MTD-1)

  • LenvatinbDrug

    Lenvatinib for patients with body weight of \<60 kg: 8 mg orally daily, for patients with body weight ≥60 kg: 12 mg orally daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of WGI-0301 in Combination with LenvatinibTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.